Market Cap 106.17M
Revenue (ttm) 0.00
Net Income (ttm) -26.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 708,400
Avg Vol 465,040
Day's Range N/A - N/A
Shares Out 111.68M
Stochastic %K 75%
Beta 1.04
Analysts Strong Sell
Price Target $6.74

Company Profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutan...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 289 910 0850
Fax: 905 481 2394
Address:
2265 Upper Middle Road East, Suite 602, Oakville, Canada
Fastcapital
Fastcapital Feb. 3 at 8:27 PM
$CRDL Where we are today vs. what’s ahead. Today: • Late-stage biotech with two advanced programs • MAVERIC in Phase 3 (orphan pericarditis) • ARCHER delivered rare Phase 2 mechanistic MRI data in myocarditis • Cash runway now extended into mid/late 2028 • Patents in place into ~2040 • Balance sheet risk largely removed What the next months can realistically bring: • MAVERIC enrollment updates • FDA interactions following ARCHER data • Patent issuance (beyond allowance) • Additional trial sites / geographic expansion • Conference abstracts / scientific presentations • Continued partner discussions (these take time, not weeks) Low volume doesn’t mean nothing is happening it usually means the market hasn’t re-rated yet. Late-stage execution + time is what changes that.
0 · Reply
Rbyild
Rbyild Feb. 3 at 7:02 PM
$CRDL With that huge 94 cent MMCAP International "put" in place, and close to 15% ownership…this can now trend higher, IMO. Our club of sorts took notice and started talking about this stock again the other day. Let’s see if we get a follow through on the chart. GLTA
0 · Reply
Covode13
Covode13 Feb. 3 at 3:26 PM
$CRDL who’s buying
1 · Reply
SeanWav
SeanWav Feb. 3 at 2:51 PM
$CRDL what’s the PT for this one in the next 2-3 years ?
1 · Reply
SeanWav
SeanWav Feb. 3 at 2:43 PM
$CRDL PAYtience pays
0 · Reply
SeanWav
SeanWav Feb. 3 at 2:43 PM
$CRDL 🚀🚀🚀🚀
0 · Reply
SeanWav
SeanWav Feb. 3 at 2:41 PM
$CRDL added more ! Hope to see this at $5+++ soon
0 · Reply
Covode13
Covode13 Feb. 3 at 1:00 PM
0 · Reply
Rbyild
Rbyild Feb. 2 at 6:58 PM
$CRDL The recent MMCAP purchase of 15,056,121 shares has now reduced the risk to take another swing, IMO. It is highly unlikely they purchased this many shares to immediately dump them on the public. It should therefore put somewhat of a floor in this range. GLTA Added more today…
1 · Reply
andywaffen
andywaffen Feb. 2 at 8:34 AM
$CRDL https://www.sec.gov/edgar/search/#/ciks=0001702123&entityName=Cardiol%2520Therapeutics%2520Inc.%2520(CRDL)%2520(CIK%25200001702123) MMCAP International Inc. SPC increased its shareholding to 17,451,746 on January 30, 2026, a purchase of 15,056,121 shares, most likely acquired from Canaccord's holdings. To me, this is a bullish signal. A deal of this magnitude is only made with insider knowledge and considerable confidence. What are your thoughts on this share purchase?
1 · Reply
Latest News on CRDL
Fastcapital
Fastcapital Feb. 3 at 8:27 PM
$CRDL Where we are today vs. what’s ahead. Today: • Late-stage biotech with two advanced programs • MAVERIC in Phase 3 (orphan pericarditis) • ARCHER delivered rare Phase 2 mechanistic MRI data in myocarditis • Cash runway now extended into mid/late 2028 • Patents in place into ~2040 • Balance sheet risk largely removed What the next months can realistically bring: • MAVERIC enrollment updates • FDA interactions following ARCHER data • Patent issuance (beyond allowance) • Additional trial sites / geographic expansion • Conference abstracts / scientific presentations • Continued partner discussions (these take time, not weeks) Low volume doesn’t mean nothing is happening it usually means the market hasn’t re-rated yet. Late-stage execution + time is what changes that.
0 · Reply
Rbyild
Rbyild Feb. 3 at 7:02 PM
$CRDL With that huge 94 cent MMCAP International "put" in place, and close to 15% ownership…this can now trend higher, IMO. Our club of sorts took notice and started talking about this stock again the other day. Let’s see if we get a follow through on the chart. GLTA
0 · Reply
Covode13
Covode13 Feb. 3 at 3:26 PM
$CRDL who’s buying
1 · Reply
SeanWav
SeanWav Feb. 3 at 2:51 PM
$CRDL what’s the PT for this one in the next 2-3 years ?
1 · Reply
SeanWav
SeanWav Feb. 3 at 2:43 PM
$CRDL PAYtience pays
0 · Reply
SeanWav
SeanWav Feb. 3 at 2:43 PM
$CRDL 🚀🚀🚀🚀
0 · Reply
SeanWav
SeanWav Feb. 3 at 2:41 PM
$CRDL added more ! Hope to see this at $5+++ soon
0 · Reply
Covode13
Covode13 Feb. 3 at 1:00 PM
0 · Reply
Rbyild
Rbyild Feb. 2 at 6:58 PM
$CRDL The recent MMCAP purchase of 15,056,121 shares has now reduced the risk to take another swing, IMO. It is highly unlikely they purchased this many shares to immediately dump them on the public. It should therefore put somewhat of a floor in this range. GLTA Added more today…
1 · Reply
andywaffen
andywaffen Feb. 2 at 8:34 AM
$CRDL https://www.sec.gov/edgar/search/#/ciks=0001702123&entityName=Cardiol%2520Therapeutics%2520Inc.%2520(CRDL)%2520(CIK%25200001702123) MMCAP International Inc. SPC increased its shareholding to 17,451,746 on January 30, 2026, a purchase of 15,056,121 shares, most likely acquired from Canaccord's holdings. To me, this is a bullish signal. A deal of this magnitude is only made with insider knowledge and considerable confidence. What are your thoughts on this share purchase?
1 · Reply
Covode13
Covode13 Feb. 1 at 8:20 PM
0 · Reply
PDM21
PDM21 Feb. 1 at 4:44 PM
$CRDL so we are going to see if other institutions follow suit here or if MMCAP will do exactly what they done the last time they owned over 5% of the company. It is illegal for large institutions to buy large sums of small caps like this and buying private placement could just be a loophole. Regardless they are confident enough that the price will run up high enough and long enough to make a profit here. How much profit is the question, watch for them to start dumping shares. They won’t sell a single share this year if they actually believe in phase 3 maverick results.
0 · Reply
Covode13
Covode13 Jan. 31 at 6:04 PM
0 · Reply
Fastcapital
Fastcapital Jan. 30 at 11:37 PM
$CRDL Let’s put the dilution narrative to rest with facts. Over the past 5 years, Cardiol’s total dilution is roughly ~100%, which is below the small-cap biotech average. Most clinical-stage biotechs moving from Phase 1 to Phase 3 dilute 150–300% over the same period. Some dilution is not only normal it’s required. Without it, trials don’t happen and companies go nowhere. What matters is what you get in return. In Cardiol’s case, dilution funded real progress: late-stage programs, strong clinical data, extended runway. Shorts have been screaming “massive dilution” for years, but the numbers simply don’t support that claim. The fact is: dilution here is manageable, industry-normal, and tied to execution not excess. If you invest in small-cap biotech, you know dilution is part of the process. The key is choosing companies that dilute below the industry average while actually executing. That’s the difference between funding progress and funding failure.
1 · Reply
Fastcapital
Fastcapital Jan. 30 at 11:31 PM
$CRDL so MMCAP increased their ownership from 2.395M shares to 17.45M. They won’t do that if they don’t know something or have full faith in CRDL. Good to see institutions are making moves just what we needed.
1 · Reply
PDM21
PDM21 Jan. 30 at 9:13 PM
$CRDL uuuummmmm go check out MMCAP internationals position now. Wtf 😳
1 · Reply
Rbyild
Rbyild Jan. 30 at 3:49 PM
$CRDL Anyone wish they would have harvested their tax losses on this turd last month?
0 · Reply
Covode13
Covode13 Jan. 30 at 12:22 AM
0 · Reply
Nick_Ams
Nick_Ams Jan. 29 at 7:54 PM
$CRDL I’ve brought this up before, but it bears repeating. We all understand that the share price shouldn’t be the management team's daily obsession. The philosophy is simple: run the business well, and the share price will take care of itself. If a team focuses solely on shareholders, they often end up making short-sighted decisions just to engineering a stock pop, which hurts us in the long run. That said, there is a middle ground. A little more transparency regarding where we stand is overdue. I hold positions in other companies where the news flow is much more consistent, and frankly, that level of communication provides a lot more peace of mind for investors. The silence here has been loud, even though we know the fundamentals are solid. It’s time to break the quiet, unlock the value, and deliver the updates we’ve been waiting for. The runway is clear and the market is watching. Let’s go, David!
0 · Reply
PDM21
PDM21 Jan. 29 at 6:37 PM
$CRDL Canacord is about to join the bag holders club
1 · Reply
Covode13
Covode13 Jan. 29 at 2:13 PM
0 · Reply
Nick_Ams
Nick_Ams Jan. 29 at 8:15 AM
$CRDL I am fully aware that this requires patience and that we are all looking for that upward momentum. That said, the underlying fundamentals are strong. That gives me the confidence to hold on to...:
1 · Reply